Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(1.17)
# 3,811
Out of 5,182 analysts
327
Total ratings
27.46%
Success rate
-10.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Buy | $65 → $50 | $24.43 | +104.67% | 6 | Apr 20, 2026 | |
| INKT MiNK Therapeutics | Reiterates: Buy | $35 | $11.14 | +214.18% | 15 | Apr 1, 2026 | |
| ANAB AnaptysBio | Reiterates: Buy | $66 | $66.59 | -0.89% | 15 | Mar 30, 2026 | |
| ATOS Atossa Therapeutics | Maintains: Buy | $7 → $25 | $5.45 | +358.72% | 15 | Mar 26, 2026 | |
| PPBT Purple Biotech | Maintains: Buy | $34 → $30 | $4.59 | +553.59% | 15 | Mar 13, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $9 → $7 | $3.47 | +101.73% | 3 | Mar 10, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $36 → $38 | $15.29 | +148.53% | 24 | Mar 9, 2026 | |
| SANA Sana Biotechnology | Maintains: Buy | $9 → $7 | $3.26 | +114.72% | 13 | Mar 4, 2026 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 | $24.95 | +28.26% | 8 | Mar 2, 2026 | |
| NVCR NovoCure | Maintains: Buy | $47 → $49 | $12.48 | +292.63% | 22 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $115 | $115.07 | -0.06% | 15 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.42 | +533.80% | 1 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $47 | $29.40 | +59.86% | 3 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $1.88 | +910.64% | 13 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $15 | $10.75 | +39.53% | 2 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $5 | $2.34 | +113.68% | 13 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.06 | +1,032.08% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $60 | $35.38 | +69.59% | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $4.09 | +462.35% | 20 | Sep 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $4.03 | +892.56% | 15 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $0.39 | +1,944.99% | 25 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $20 | $0.93 | +2,050.77% | 10 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $9.62 | +274.22% | 9 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $560 → $280 | $8.30 | +3,273.49% | 17 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.45 | +226.53% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $2.56 | +1,071.88% | 7 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.83 | +536.04% | 15 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $183 | $2.80 | +6,421.79% | 12 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.53 | - | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $2.46 | - | 1 | Apr 25, 2024 |
Agios Pharmaceuticals
Apr 20, 2026
Maintains: Buy
Price Target: $65 → $50
Current: $24.43
Upside: +104.67%
MiNK Therapeutics
Apr 1, 2026
Reiterates: Buy
Price Target: $35
Current: $11.14
Upside: +214.18%
AnaptysBio
Mar 30, 2026
Reiterates: Buy
Price Target: $66
Current: $66.59
Upside: -0.89%
Atossa Therapeutics
Mar 26, 2026
Maintains: Buy
Price Target: $7 → $25
Current: $5.45
Upside: +358.72%
Purple Biotech
Mar 13, 2026
Maintains: Buy
Price Target: $34 → $30
Current: $4.59
Upside: +553.59%
SAB Biotherapeutics
Mar 10, 2026
Maintains: Buy
Price Target: $9 → $7
Current: $3.47
Upside: +101.73%
Olema Pharmaceuticals
Mar 9, 2026
Maintains: Buy
Price Target: $36 → $38
Current: $15.29
Upside: +148.53%
Sana Biotechnology
Mar 4, 2026
Maintains: Buy
Price Target: $9 → $7
Current: $3.26
Upside: +114.72%
Arcus Biosciences
Mar 2, 2026
Reiterates: Buy
Price Target: $32
Current: $24.95
Upside: +28.26%
NovoCure
Feb 26, 2026
Maintains: Buy
Price Target: $47 → $49
Current: $12.48
Upside: +292.63%
Feb 23, 2026
Downgrades: Neutral
Price Target: $115
Current: $115.07
Upside: -0.06%
Feb 17, 2026
Initiates: Buy
Price Target: $9
Current: $1.42
Upside: +533.80%
Dec 19, 2025
Maintains: Buy
Price Target: $36 → $47
Current: $29.40
Upside: +59.86%
Nov 25, 2025
Reiterates: Buy
Price Target: $19
Current: $1.88
Upside: +910.64%
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $15
Current: $10.75
Upside: +39.53%
Nov 6, 2025
Maintains: Buy
Price Target: $4 → $5
Current: $2.34
Upside: +113.68%
Oct 14, 2025
Initiates: Buy
Price Target: $12
Current: $1.06
Upside: +1,032.08%
Oct 6, 2025
Assumes: Buy
Price Target: $60
Current: $35.38
Upside: +69.59%
Sep 10, 2025
Reiterates: Buy
Price Target: $23
Current: $4.09
Upside: +462.35%
Aug 27, 2025
Maintains: Buy
Price Target: $32 → $40
Current: $4.03
Upside: +892.56%
Aug 11, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $0.39
Upside: +1,944.99%
Jul 7, 2025
Maintains: Buy
Price Target: $40 → $20
Current: $0.93
Upside: +2,050.77%
Jul 1, 2025
Reiterates: Buy
Price Target: $36
Current: $9.62
Upside: +274.22%
Apr 16, 2025
Maintains: Buy
Price Target: $560 → $280
Current: $8.30
Upside: +3,273.49%
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $2.45
Upside: +226.53%
Mar 31, 2025
Reiterates: Buy
Price Target: $30
Current: $2.56
Upside: +1,071.88%
Mar 27, 2025
Reiterates: Buy
Price Target: $18
Current: $2.83
Upside: +536.04%
Mar 26, 2025
Reiterates: Buy
Price Target: $183
Current: $2.80
Upside: +6,421.79%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.53
Upside: -
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $2.46
Upside: -